Skip to content

A Trial in Mini-invasive Pilonidal Sinus Disease Surgery

Laser Ablation Versus Fibrin Glue in Mini-invasive Pilonidal Sinus Disease Surgery: a Prospective Randomized Controlled Trial

Status
Enrolling by invitation
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06964763
Enrollment
188
Registered
2025-05-09
Start date
2023-09-01
Completion date
2029-12-17
Last updated
2025-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pilonidal Disease

Keywords

pilonidal sinus disease, laser ablation, fibrine glue, randomized trial, prospective study

Brief summary

Pilonidal sinus disease is a chronic acquired disease leading to significant morbidity and healthcare costs in young man and women. Despite different treatment methods, the disease relatively often leads to postoperative complications and recurrence.(8). Advantages of mini-invasive techniques include: quicker recovery and earlier return to work and high patient satisfaction. Randomized studies are rare and this applies especially to newer mini-invasive techniques. The purpose of the investigators prospective study is to randomly compare the mini-invasive laser ablation technique to the mini-invasive fibrin glue treatment in pilonidal sinus disease surgery.

Detailed description

This is a multicenter study comparing two mini-invasive treatmnet options in pilonidal sinus disease. The study is carried out in four hospitals in Uusimaa county of Finland (Jorvi hospital, Porvoo hospital, Lohja hospital and Hyvinkää hospital). Patients, who are 18 or above, with a symptomatic primary pilonidal sinus disease are eligible for the study. On the day of surgery, the patient is randomly assigned to one of the two surgery groups. The main variable of our study is the healing rate at 2 months after surgery. Other variables to be studied are: postoperative complications, length of sick leave, time for returning to everyday life, recurrence rate and the effects of PSD and PSD surgery on the patient's quality of life. A cost analysis will be performed. Risk factors such as overweight, pubic hair, smoking and associated diseases such as diabetes will also be analyzed. According to the power calculation, the investigators need 94 patients in each group to ensure the success of the study.

Interventions

PROCEDUREsurgery + laser

laser

PROCEDUREsurgery + fibrine glue

fibrine glue

Sponsors

Helsinki University Central Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* primary pilonidal sinus disease * age 18 and above

Exclusion criteria

* recurrent pilonidal sinus disease * age under 18 * inability to understand Finnish or Swedish (the questionnaires are in Finnish and Swedish only, the two official languages of Finland)

Design outcomes

Primary

MeasureTime frameDescription
Healing rate2 months after surgeryHealing rate will be assessed by a questionnaire and a phone call
Quality of life2 months after surgeryQuality of life will be assessed by a questionnaire, the RAND 36-Item Health Survey

Secondary

MeasureTime frameDescription
Postoperative complications2 - 3 months after the surgeryPostoperative complications will be assessed by a phone call and clinical examination
Recurrence rate1, 3 and 5 years after surgeryFollow-up at 1, 3 and 5 years by assessing electronic medical records to reveal recurrences
Recovery time2 months and 1 year after surgeryThe time it has taken fot the patient to return to everyday life is assessed by a questionnaire and through medical records
Sick leave2 months and 1 year after surgeryLength of sick leave will be assessed by a questionnaire and medical records
Cost analysisAt 2 months after surgeryCompare the price for the two surgical treatments

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 15, 2026